{"id":"W2790862281","doi":"10.1200/jco.2018.36.6_suppl.431","title":"Enfortumab vedotin (EV) in patients (Pts) with metastatic urothelial carcinoma (mUC) with prior checkpoint inhibitor (CPI) failure: A prospective cohort of an ongoing phase 1 study.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Clinical endpoint; Oncology; Nausea; Population; Rash; Metastatic Urothelial Carcinoma; Cancer; Adverse effect; Gastroenterology; Clinical trial; Bladder cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006443894,0.0003975135,0.0006121458,0.0001977325,0.0002940466,0.0005572416,0.0002257519,0.0003879812,0.001493068],"category_scores_gemma":[0.0006207121,0.0002167145,0.0005350275,0.0003009232,0.0002179727,0.00041261,0.0002675435,0.0008469776,0.0003322661],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004258341,"about_ca_system_score_gemma":0.0005643347,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007334041,"about_ca_topic_score_gemma":0.00206348,"domain_scores_codex":[0.9998124,0.00006366683,0.00001169798,0.0000410721,0.00002825128,0.00004288544],"domain_scores_gemma":[0.9996916,0.00004922373,0.00008461863,0.00002381671,0.00002178706,0.0001289488],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.252124,0.02092369,0.4764661,0.0007982985,0.00206113,0.00133875,0.000564498,0.003101083,0.0406106,0.000227131,0.005186437,0.1965983],"study_design_scores_gemma":[0.06775257,0.3606429,0.5395439,0.0001452271,0.00190577,0.003628049,0.0004027878,0.003627507,0.007861287,0.0003389019,0.01410483,0.00004637604],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9979487,0.0008966461,0.00009532822,0.00004472152,0.000008793332,0.0001772592,0.0003684996,0.000008683264,0.0004514006],"genre_scores_gemma":[0.997393,0.0006047846,0.0002335957,0.0001040886,0.00002044787,0.0001570432,0.001017687,0.000004265376,0.0004649548],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001493068,"threshold_uncertainty_score":0.00499481,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04831238446769352,"score_gpt":0.4116602642828975,"score_spread":0.3633478798152039,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}